Whitehawk Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Whitehawk Therapeutics, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage oncology biotech with promising ADC technology but requiring significant capital and clinical validation before commercialization. The company has zero revenue with estimated figures missing significantly, while earnings are negative. The company is currently unprofitable and not forecast to become profitable over the next 3 years. However, the strategic.
What is Whitehawk Therapeutics, Inc.'s industry? Whitehawk Therapeutics, Inc. (whitehawktx.com) operates in Biotechnology / Oncology Therapeutics. AskCyborg classifies Whitehawk Therapeutics, Inc. under Biotechnology / Oncology Therapeutics in its company registry.
Whitehawk Therapeutics is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antib...
Cyborg Score thesis
Early-stage oncology biotech with promising ADC technology but requiring significant capital and clinical validation before...
Read the full analyst-debate transcript →Get the Latest Whitehawk Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeWhitehawk Therapeutics, Inc. Overview
Pro stress-test →Whitehawk Therapeutics is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
Strategic Profile
Pro stress-test →The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. With a preclinical-stage focus and partnerships in biomarker-driven oncology research, the company is positioning itself in the competitive ADC therapeutics space where multiple players are advancing novel approaches to cancer treatment.
Competitive Landscape
Pro stress-test →Whitehawk operates in the crowded ADC oncology space competing with established biotech companies and other preclinical programs. Key competitive dynamics include differentiation through ADC engineering improvements, biomarker selection, and partnership strategies for clinical development and commercialization.
Industry Context
Whitehawk Therapeutics, Inc. operates in Biotechnology / Oncology Therapeutics.
Key facts
Founded: 2007 · Headquarters: Morristown, New Jersey · Employees: 22 · Revenue: $0 · Market cap: $123-134M